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Abstract (250 words) 
Purpose 
Specialized Palliative Care (SPC) is currently underutilized or provided late in cancer 
care. The aim of this systematic review and meta-analysis is to critically evaluate the 
impact of SPC on patients’ Health-Related Quality of Life (HRQoL).  
Methods 
Five databases were searched through June 2016. Randomized Controlled Trials 
(RCTs) and prospective studies using a pre- and post- assessment of HRQoL were 
included. The PRISMA reporting statement was followed. Criteria from available 
checklists were used to evaluate the studies’ quality. A meta-analysis followed using 
random-effect models separately for RCTs and non-RCTs.  
Results 
Eleven studies including five RCTs and including 2939 cancer patients published 
between 2001 and 2014 were identified. There was improved HRQoL in patients with 
cancer following SPC especially in symptoms like pain, nausea and fatigue as well as 
improvement of physical and psychological functioning. Less or no improvements 
were observed in social and spiritual domains. In general, studies of inpatients 
showed a larger benefit from SPC than studies of outpatients whereas patients’ age 
and treatment duration did not moderate the impact of SPC. Methodological 
shortcomings include high attrition rates, low precision and power and poor reporting 
of control procedures.  
Conclusions 
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The methodological problems and publication bias call for higher-quality studies to be 
designed, funded and published. However, there is a clear message that SPC is multi-
disciplinary and aims at palliation of symptoms and burden in line with current 
recommendations.  
 
Keywords: palliative care, specialized palliative care, cancer, quality of life, meta-
analysis 
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Introduction 
Cancer is a public health and epidemiological concern with estimated 14 million new 
cases per year worldwide, two thirds of which are expected to die within one year [1]. 
A recent statement from the American Society of Clinical Oncology (ASCO) came to 
recognize that patients with advanced incurable cancer face complex physical, 
psychological, social, and spiritual consequences of disease and its treatment [2]. 
Moreover, the care for these patients should include an individualized assessment of 
each patient’s needs, goals, and preferences throughout the course of the illness [3]. 
For these patients, oncological treatment at late stages of disease has limited benefits 
in terms of prolonging life [4–7]. Furthermore the ASCO statement recognizes that 
standard oncology care for these patients remains focused on disease-directed therapy, 
often without realistic conversations about its potential benefits and limitations and 
the potential role of Palliative Care (PC). [2]. This results in increased aggressiveness 
of care and subsequently in increased toxicity and worsening of physical symptoms, 
whilst neglecting to address the physical, psychological and spiritual impact of the 
disease and its treatment [8], with emerging evidence that aggressive care can actually 
decrease patients’ Health-Related Quality of Life (HRQoL) before death [9].  
Consequently, PC comes to address this challenge for patients with advanced cancer. 
The World Health Organization (WHO) defines PC as provision of active, holistic 
care of patient with advanced, progressive illness focusing on the management of pain 
and other symptoms and provision of psychological, social and spiritual support with 
the aim to improve HRQoL [10]. HRQoL is a multidimensional concept, which 
interprets an individual’s health status. Any increase in disease-related symptoms is 
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also related to a decrease of HRQoL [11]. To achieve improvement in HRQoL, PC 
aims to control for the burden of symptoms, provide psycho-social support, co-
ordinate care for patients and families and provide hospice services [12–14].  
Specialized PC (SPC) underscores the specialist training in PC that specialist 
clinicians undergo, and the certification that currently exists for PC as a new medical 
specialty, whilst generalist or basic PC refers to the basic symptom control and care 
provided by non PC specialists, e.g. general physicians or oncologists [15].  
SPC provision has been very rapidly growing the last decade in the US [16] and 
associated with improvements in HRQoL in a non-cancer specific review [17]. 
However, methodological shortcomings of research studies evaluating SPC delivery 
are evident from non-disease specific SPC studies including contamination of control 
groups as well as limitations in recruitment, attrition and adherence which 
compromise the robustness of the impact of SPC [18]. High attrition rates and 
heterogeneity of study population and description of procedures in both the 
intervention and control arms are other issues from similar studies [19]. These 
methodological issues are reflected in limitations of evaluation of health care services 
where heterogeneity is identified in terms of interventions and methods [20].  
There are recommendations suggesting that SPC should be integrated to oncological 
treatment to improve patients’ HRQoL [18, 21–24]. In fact, ASCO recommends 
offering SPC with oncological treatment for all patients treated for metastatic cancer 
or with uncontrolled symptoms [25, 26]. However, more evidence is needed on how 
to implement these recommendations [18]. Thus, there is a need to have more 
concrete, solid evidence of the impact of SPC in HRQOL for policy making since it is 
generally accepted that HRQoL is the most significant endpoint in SPC studies. The 
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aim of this systematic review and meta-analysis is to evaluate the impact of SPC on 
cancer patients’ HRQoL. 
Methods 
The protocol for the systematic review was registered with the PROSPERO 
international prospective register of systematic reviews (Registration number: 
CRD420150161121) in January 2015. The PRISMA statement reporting items for 
systematic reviews and meta analyses was followed [27]. The main assessed outcome 
was HRQoL.  
Eligibility criteria 
Studies published in peer-reviewed journals were eligible to be reviewed, provided 
that they included patients > 18 years old, diagnosed with any primary and metastatic 
cancer. Eligible studies should be evaluating interventions aiming to provide SPC to 
cancer patients by SPC service and assessing HRQoL as an outcome. For PC, the 
WHO definition was used to assess eligibility [10]. The WHO definition was used as 
it clearly describes palliative care. This was the first step in identifying whether PC 
was used. The second was to assess whether SPC was delivered as care provided from 
professionals/teams with training/expertise in PC, who coordinate or provide 
comprehensive care for cancer patients [18, 28]. Studies that provided supportive care 
or any other psychosocial intervention or care that was not coordinated or provided by 
SPC team were excluded. Studies that included cancer patients together with other 
patient groups or where HRQoL was not assessed using standardized and validated 
questionnaires were also excluded. Both randomized and non-randomized controlled 
trials including prospective and retrospective studies with pre- and post- assessment 
were included. Cross-sectional and qualitative studies as well as pilot studies were 
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excluded. No publication date restriction was used and only studies published in 
English were included for pragmatic reasons.    
Search strategy, study selection, and synthesis 
The initial search was conducted between January and March 2015 and updated in 
June 2016. The search keywords were developed around three conceptual areas: the 
type of care, the type of patients, and the measured outcome. The following search 
strategy was applied for all the databases: (‘palliative * car*’ OR ‘comfort* car*’ OR 
‘end?of?life car*’ OR ‘terminal car*’ OR ‘support* car*’ OR ‘hospice’) AND 
(‘cancer patient*’ OR ‘advance cancer patient*’ OR ‘patient*’) AND (‘quality of life’ 
OR ‘health?related quality’). The search was in line with the PRESS checklist [29]. 
The search strategy applied for all the databases is available as Electronic 
Supplementary Material. A pilot-testing scoping search identified 5440 studies.  
The following databases were searched: EMBASE, CINAHL, MEDLINE, PsycINFO, 
and PubMed. Two authors (MI, MK) who imputed all the identified titles in a 
database conducted the searches independently. After removing duplicates, the titles 
were screened based on the eligibility criteria and inclusion of at least two keywords 
in the title. Three authors (AK, MI, MK) then screened abstracts independently. 
Eligible studies based on abstract were included in full text screening and data 
extraction. After abstract screening, hand searches of included studies’ reference lists 
followed. 
During the full-text screening, an assessment form was used to extract the data from 
the identified studies. Three authors (AK, MI, MK) extracted data independently with 
crosschecking between them. Discrepancies were discussed and resolved aiming to 
reach mutual agreement. The final studies were provided to a fourth author (HC) with 
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clinical experience to provide clinical evaluation (Figure 1) to ensure that the 
intervention described was SPC (i.e. provided by teams with specialist training in 
PC). The evidence from the included studies was synthesized using a narrative 
analysis approach. 
Quality appraisal  
Three authors (AK, MI, HC) conducted a quality assessment of included studies. The 
consistency among the quality ratings was assessed using the inter-rater reliability 
(IRR) kappa. Discrepancies were discussed and resolved in consensus meetings. The 
quality criteria were adapted from relevant quality checklists [30–38]. The main areas 
assessed were on the procedures of the randomization, the intervention, the 
appropriate description of the patient-related aspects, and the internal and external 
validity of the study. All studies were scored (0-2) on each quality criterion, and a 
summative score was calculated for each study. Highest score possible for RCTs was 
32 and for non-RCTs 22. Scores were interpreted in terms of percentage (i.e. 
obtaining 13/26 points = 50%). The Quality Assessment Criteria List is available as 
Electronic Supplementary Material.  
Meta-Analysis 
None of the studies had a score that significantly differed from the mean of the 
summative score derived from the quality assessment. Therefore all studies were 
included in the meta-analysis. The meta-analysis was run based on the principles of 
the random-effects models, which recognize the differences in error variation between 
the studies. The standardized mean difference (SMD) was used, as it takes into 
account that HRQoL was measured using different tools and calculated using the 
equation: 
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𝑆𝑀𝐷 =  
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑚𝑒𝑎𝑛 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑔𝑟𝑜𝑢𝑝𝑠
𝑆𝐷 𝑜𝑓 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑎𝑚𝑜𝑛𝑔 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠
 
The fixed-effects model was run first to estimate the heterogeneity between the 
studies (Q and I2 statistic) and then the random-effects models if heterogeneity was 
significant. Moreover, sensitivity analyses were run to show the robustness of the 
findings based on the decisions made earlier regarding the inclusion criteria. When a 
study used a score to assess overall quality of life, this was used as an outcome 
whereas in the studies where this variable was not used, a summative score of quality 
of life based on measured outcomes was used. For sub-group analyses, mixed effects 
models were used to assess the potential predictive value of certain factors for the 
estimation of the effect size (Cohen’s d). The Q statistic was used to determine if a 
factor significantly differentiates the effect size between the groups. Similarly, to 
investigate the predictive role of age and treatment duration a meta-regression model 
was used. When the effect size estimates were not reported, they were computed 
through the available formulas or were transformed to the effect size indexes used in 
the current meta-analysis. The factors used in the models were trial design (RCTs and 
non-RCTs), type of cancer, site of treatment (inpatients, outpatients, and both), SPC 
duration, and patients’ age. Publication bias was also investigated to detect 
asymmetries between studies.  
Results 
Study selection 
The initial search identified 8649 records from five databases and following all 
screening stages eleven studies were included in the systematic review (Figure 1). 
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Exclusions were mainly based on type of treatment, language, study population and 
research design with the majority not reporting any intervention or SPC.  
Study characteristics 
Eleven studies (N = 11) were included in the review with a total of 2939 patients with 
gastrointestinal tract, lung, breast, female genitals, prostate, male genitals, kidney, 
vesical, urethra, lymphoma, skin/melanoma, sarcoma, colorectal, head and neck, 
pancreatic, stomach, liver, bladder, esophageal, bile duct, and ovarian cancer. Three 
studies were conducted in the USA, two in Canada and one each in Japan, Norway, 
Sweden, Switzerland, Denmark and Turkey published between 2001 and 2014. Data 
were collected between 1995 and 2011. Five were RCTs (Table 1) and six were 
prospective studies that assessed HRQoL in a cohort of patients before and after 
implementing SPC (Table 2). Of the five RCTs, two were clustered. Two RCTs 
reported using participant blinding and in a third one the patients in the intervention 
arm were not aware of the other arm. All RCTs used a stratified approach in 
randomization.   
The mean age of the patients ranged from 52.6 to 68 years with one study reporting a 
median of 72. Four studies (36.4%) used inpatients; three (27.2%) used outpatients; 
four studies (36.4%) used both. For example, SPC was delivered in a PC unit or clinic 
[11, 39–41], at home [42, 43], at community services [44] or used a combination of 
home-based care and clinical appointments [45–47]. Seven studies (58.3%) specified 
that they included patients with metastatic cancer, whilst four studies reported stage of 
cancer as stage III or IV. Three studies specified that the referral to SPC was within 8 
weeks [42, 45] or up to twelve weeks after diagnosis [47]. Only three studies (27.2%) 
provided prognosis information for included patients at study entry and it ranged from 
six to twenty-four months.  
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There was variation of tools used to measure HRQoL; the EORTC QLQ C-30 [48], 
the Functional Assessment of Cancer Therapy (FACT) measurement system [49, 50], 
the Functional Assessment of Chronic Illness Therapy-Palliative Care (FACIT-pal) 
[51, 52] and its lung subscale (FACT-L) [53], the spiritual subscale (FACIT-sp) [54], 
the QUAL-E [55], the McGill QoL Questionnaire [56], the Schedule for the 
Evaluation of Individual Quality of Life – Direct Weighting version (SEIQoL-DW) 
[57], and the Assessment of Quality of Life at the End of Life (AQEL) [58].  
Intervention and control procedures 
The SPC was clearly outlined in two studies [45, 47] while another two studies [11, 
59] failed to clearly report details on SPC delivery but described SPC provided by a 
multi-professional team with specialist training in PC. A fourth study also did not 
report on the intervention but referred to a methodological paper [44]. A fifth study 
had no information on what the SPC entailed other than who delivered care [41]. 
Almost half of the studies reported the theoretical background or guidelines of the 
SPC used. For example, one study [47] reported using the chronic care model 
focusing on case management in relation to communication with family and clinicians 
in terms of life priorities, goals and preferences. Case management SPC was also used 
in another study [39] whilst two studies [42, 45] reported using an approach focusing 
on symptom assessment, decision-making, care co-ordination and patients’ goals and 
needs.  
All studies reported on the team or health professionals delivering the SPC except one 
which was an inpatient study that usually incorporates a multidisciplinary team of 
professionals [59]. Six studies (54.5%) reported a multi-disciplinary team delivering 
the intervention. All of the teams included PC-trained nurses and clinicians and some 
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of them included psychologists, social workers and other specialized professionals. 
Only five studies (45.5%) reported providing training to the team delivering the 
intervention [39, 42, 44–46]. 
The control groups’ procedures were reported in four RCTs as ‘usual care’ [39, 42, 
45, 47], while the fifth RCT reported no information [46]. The SPC group procedures 
ranged from daily to monthly sessions and from one-to-two weeks to four months 
(Table 3).  
Study outcomes 
We report the outcomes of the five RCT’s first. In terms of the baseline assessment, 
two [42, 47] reported no differences in HRQoL between the intervention and control 
arms at baseline and one [39] provided only baseline differences on symptoms as 
measured by the Edmonton Symptom Assessment System (ESAS). The outcome 
measures were worse at baseline in the intervention group with one study reporting 
more genitourinary cancer cases in the intervention group [45]. Another study 
reported differences in housing, access to informal help, home care nursing and living 
situation [46].  
In terms of the primary endpoint, all of the RCTs with the exception of one study 
[46], showed some evidence of improvement of HRQoL in the intervention compared 
to the control arm (Table 1). The study that did not, investigated the impact of a 
newly founded PC unit, which was set up in 1994, providing SPC in collaboration 
with existing community services in Norway, with the study being carried out 
between 1995-1997. Neither the PMU staff nor the community workers had any 
experience with the overall concept and the new routines that were to be 
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implemented. Also, the intervention was strongly based on the existing community 
service.  
The study by Bakitas et al followed findings with intention-to-treat analyses which 
confirmed the positive impact of SPC on HRQoL [47]. Another study of inpatient 
SPC by Oczelik et al, reported improvements on role, emotional and social 
functioning and on the global quality of life item [39]. Sustained benefits were 
reported in the study by Zimmermann et al, four months post-intervention, but not at 
the pre-specified time of analysis of the primary outcome which was change in the 
FACIT-Sp score at 3 months [45]. Finally the study by Temel et al, reported clinically 
meaningful improvements on HRQoL [42].   
All non-randomized studies showed significant improvements in HRQoL following 
the SPC intervention (Table 2). The study by Bishoff et al, showed significant 
improvement in the general quality of life items, and also in symptoms like pain and 
fatigue between baseline and first and second follow-ups, with sustained benefits 
twelve weeks post-intervention [40]. Similarly Cohen et al reported improvements in 
physical functioning as well as in physical and psychological domains during the first 
week of admission to a SPC unit [59]. The study by Melin-Johanson et al [43] found 
that social and existential domains did not improve.  
Looking at both RCTs and non-randomized studies together, there were some other 
important findings, which are useful at interpreting the impact of SPC on HRQoL. 
SPC delivery led to lower symptom intensity overall [39, 47] and specifically on pain 
[11, 40, 59], fatigue, [40] and nausea [43]. There were also improvements in 
symptoms of depression [40, 59], mood [42], anxiety [40, 43, 59] and spiritual well 
being [40, 59]. Patients who received SPC were more likely to die at home [44, 46] 
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and be more satisfied with care [39, 45]. There were two studies also reporting a 
positive impact on survival [42, 47].  
Physical functioning was not improved by SPC in the Jordhoy et al and Ozcelik et al 
trials [39, 46]. Additionally in the Jordhoy et al trial emotional functioning and pain 
and in Ozcelik et al cognitive functioning did not improve. Finally, in the Melin-
Johansson et al trial [43] the social and existential functioning of patients remained 
the same.  
Quality assessment 
The inter-rater reliability on quality assessment was high (kappa = 0.82). The 
summative quality scores ranged from 36.4% to 78.1% demonstrating that studies 
achieved the methodological standards on a moderate degree with an average of 
56.8% quality score (Table 4). The quality of RCTs was higher than non-RCTs 
because of better reporting and consideration of research design methods with average 
summative quality scores of 65.0% and 50.0% respectively. Most studies had well 
defined objectives and hypotheses.  
Six studies were either underpowered or failed to report any power calculation [11, 
40, 43, 44, 46, 59]. The precision of the included studies was also problematic since 
the Confidence Intervals (CIs) around the estimated treatment effect size were either 
wide with high possibilities of random error [11, 44, 46, 59], or rather wide with 
moderate possibilities for random error for the rest of the studies. In terms of 
reporting, two studies [39, 46] did not report the number of eligible patients. 
Attrition rates for each study were calculated using the reported numbers of 
participants at baseline and at the end of the study as well as the reasons for attrition 
(Figure 2). The average attrition rates were between 29.1% - 46.6% with three 
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outliers, two of them with reported attrition of 0% [39, 43] and a third study with 
reported attrition of 75.1% [46]. Using information in five studies [11, 42, 45, 47, 59] 
there were 190 deaths and 210 withdrawals and for two studies reasons for attrition 
were not reported [40, 59]. For another study [41], the third week post- intervention 
was used to calculate attrition since the HRQoL data reported are from that point.  
Meta-analysis 
The included RCTs were homogeneous to be analyzed with fixed-effects models (Q= 
8.22, p= .084, I2= 51.32 %) but there was heterogeneity in non-RCTs (Q= 34.889, p< 
.001, I2= 85.67%). There was a positive moderate impact of SPC in HRQoL (SMD, 
0.28; 95% CI, 0.16 to 0.41; p< .001) (Figure 3). There was also a marginally 
significant publication bias (Kendall’s tau = 0.673, p = .004) favouring studies with 
positive effect sizes1.  
There were non-significant differences on the impact of SPC on HRQoL between 
RCTs and non-RCTs (p = .990), types of cancer (p = .627) and between inpatients, 
outpatients and both (p = .172). However mixed-effects analysis showed that SPC had 
a positive impact in studies using inpatients (SMD, 0.55; 95% CI, 0.17 to 0.92; p = 
.004) or both (SMD, 0.18; 95% CI, 0.08 to 0.27; p < .001) but non-significant effect 
for outpatients (SMD, 0.20; 95% CI, -0.03 to 0.44; p = 0.89).  
The meta-regression analyses showed that the patients’ age (b = -0.016, 95% CI = -
0.038 - 0.007, z = -1.37, p = .17) and treatment duration (b = -0.044, CI = -0.094 - 
0.006, z = -1.71, p = .087) were not significant predictors of the overall effect size on 
HRQoL. The residual error sum of squares was not significant (Q (4) = 8.97, p = .06), 
                                                        
1 The Duval and Tweedie’s trim and fill statistic showed that six studies were missing from the 
published literature that could establish symmetry on the funnel plot, which even if considered not 
favoring SPC, the standardized mean effect would remain significant and would still not traverse the 
zero axis, with d= 0.117 (95% CI -0.012, 0.245). 
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suggesting that the specialist delivering the intervention largely explained 
heterogeneity (I2 = 55.40%). 
Discussion 
This review suggests that SPC decreases suffering and improves HRQoL in patients 
with advanced/metastatic cancer. There is evidence of improvement in palliation of 
symptoms, like pain, nausea, fatigue and improvement of physical and psychological 
functioning and to a lesser degree social and spiritual. Furthermore in two RCTs, 
there is evidence of improvement in survival [42, 47]. The meta-analysis also 
highlights a more pronounced impact of the SPC intervention in studies including 
inpatients (or both inpatients and outpatients). This may relate to the fact that 
inpatients are more symptomatic and more in need of SPC. Also, patients’ age and 
treatment duration did not moderate the impact of SPC on HRQoL. On the other 
hand, studies using a PC team had higher impact on HRQoL compared to case 
management teams.  
This review suggests that the SPC care model in all studies was mostly multi-
disciplinary, and aimed at the multi-dimensional nature of suffering. In conducting 
this review, careful consideration was given to the definition and criteria used to 
define SPC. In the literature, SPC members have training in PC and either work 
with or are able to refer to the other members of a multidisciplinary team [60]. 
In practical terms, in the papers we looked for wordings describing that the 
personnel delivering care included specialist PC doctors or nurses, hence studies 
provided by psychologists or other health care professionals without PC training 
and without the ability to work with established PC teams, were excluded.  
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In interpreting the meta-analysis the marginally significant publication bias for RCTs 
needs to be considered. Therefore, journals are advised to publish high quality SPC 
studies based not only on novelty but also on robust methodology and also to publish 
protocols or the trials’ full data sets. Researchers, ethics committees and funders are 
also advised to consider these actions [61].  
These evidence can support current recommendations, which recognize the 
importance of SPC in improving patients’ symptoms, HRQoL and satisfaction, and 
suggesting that SPC should be considered early in the course of illness of all patients 
with advanced/metastatic cancer [25, 26].  
There are a number of methodological issues in reported studies including high 
attrition rates, low precision, low power and poor of the intervention and control 
procedures. Attrition is a serious limitation with high attrition rates of 40% also 
identified in non-cancer specific SPC trials [18]. Only three studies used multiple sites 
calling for more multi-institutional studies to ensure translation of evidence in 
different health care settings. Furthermore, there has been a multitude of tools used 
for assessment of HRQoL, with one study using a single-item question [40]. Another 
important limitation is that in the included RCTs, there is no available information as 
to the quality of the standard care offered to patients. This lack of standardization can 
impact the robustness of recommendations and reflects a recent systematic review 
which showed that only one third of the Best Supportive Care studies offered a 
detailed description of control procedures [62].  
The included studies reflect the findings from a recent review which suggest that 
strong benefits come from integrated care models involving a multidisciplinary team 
[63]. Moreover, the included studies varied from predominantly phone-based 
educational interventions using a SPC nurse and on-going patient and caregiver 
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follow up [47], outpatient SPC-team approach focusing on illness understanding and 
management [42], case management [39], home-visit approach for symptom control 
and support [43] and nurse-led symptom control [11] among others. Another issue 
identified in terms of delivery is the optimal training in PC of staff and the necessary 
skill mix in a service providing SPC. Almost half of the included studies did not 
report training to the team delivering the intervention to ensure systematic 
implementation. Standardization in methodology should reflect the efforts to 
standardize SPC through the development of PC programs worldwide, board 
certification programs in the US and SPC programs in Europe, Canada and Australia 
[64, 65]. Systematic evaluation is important because there are studies suggesting 
differences in the proficiency of oncologists to manage pain [66] or on comfort to 
provide basic PC [18]. 
Given the fact that current oncological treatment is usually expensive and intensive 
[67], and the fact that for example in the US, high healthcare costs are not translated 
into higher quality of care [68], the implementation of SPC should become a public 
health planning priority [69]. In more than half of the U.S National Cancer Institute’s 
Centres there are SPC services [70] which also increase mostly for inpatients or 
patients at home [71–73]. Even so, SPC is underutilized [74] so evaluating the 
implementation of SPC is important.  
Limitations of this review include the fact that the reviewed studies come 
predominantly from countries with advanced health care systems and available PC 
services. There are no studies from developing countries, where the availability of PC 
is a much bigger problem [75]. Also the included study criteria were strict to ensure 
that relevant studies were selected but this led to a small number of studies.  
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There is a need for further clinical trials to include HRQoL as an end-point together 
with other parameters including survival, symptom burden, satisfaction with care, 
caregivers’ HRQoL and health care system resources use and costs. This can further 
facilitate the delivery and quality of services to patients. It is also important that such 
studies are also undertaken in less developed countries.  
Conclusions 
The strength of the impact of SPC on HRQoL is particularly reflected in evidence on 
the sustainability of benefits [40, 45]. This review and future studies can help to shape 
health care policy in this field and to call for higher quality SPC trials published. The 
implementation of careful evaluation should persuade policy makers to invest in SPC 
services.  
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 Table 1 Study characteristics of randomized controlled trials (RCTs) included in the review.  
 
Study information Study 
period 
Recruitment procedures Participants Cancer type and 
treatment 
Data collection 
and tools used 
SPC delivery Outcome 
Bakitas et al 
 
2009 
 
USA 
 
Randomization level: 
patients 
 
Blinding: Yes 
 
Stratification a: Yes (by 
randomization scheme, 
disease and blocked 
within strata) 
 
Multiple cites 
2003-
2007 
Inclusion criteria: within 8 - 
12 weeks of a new diagnosis 
of gastrointestinal tract 
(unrespectable stage III or IV), 
lung (stage IIIB or IV non–
small cell or extensive small 
cell), genitourinary tract (stage 
IV), or breast (stage IV and 
visceral crisis), lung or liver 
metastasis, estrogen receptor 
negative, human epidermal 
growth factor receptor 2 
positive cancer. 
  
Exclusion criteria: a) 
impaired cognition (<17 on a 
modified Mini-Mental State 
Examination), b) an Axis I 
psychiatric disorder 
(schizophrenia, bipolar 
disorder), or c) active 
substance use. 
Eligible b: 681 
 
Total sample: 322 
(47% of eligible) 
 
Total IG c: 161 (50% 
of total) 
 
Age: IG: M = 65.4 
(10.3) CG d: M = 65.2 
(11.7) 
 
Gender: 60.2% M (IG: 
62.1% M CG: 58.2% 
M) 
 
Inpatients and 
outpatients  
Cite: cancer of the 
gastrointestinal tract 
(41%), lung (36%), 
cancer of the 
genitourinary tract 
(12%), and breast 
(10%) 
 
Metastatic: NR 
 
Stage: III, IV 
 
Previous treatment: 
parenteral 
chemotherapy or 
radiotherapy. 
 
Prognosis (T1): 
approx. 1 year 
Endpoints: 
HRQoL e, 
symptom 
intensity, resource 
use, mood 
 
Tool for 
HRQoL: FACIT-
Pal f 
 
 
 
Team: Delivered by 
two advanced 
practice nurses with 
palliative care 
specialty training, a 
palliative care 
physician and a nurse 
practitioner. 
 
Place: inpatient 
shared medical 
appointment and 
telephone 
consultations.  
 
 
 
Confirmed 
by intention-
to-treat 
analyses (p = 
.02). 
 
  
Jordhøy et al  
 
2001 
 
Norway 
 
Randomization level: 
Community healthcare 
districts (clustered) 
1995-
1999 
Inclusion criteria: a) 
incurable malignant cancer 
diagnosis; b) life expectancy 
between 2 - 9 months; c) > 18 
years old 
  
Exclusion criteria: NR 
 
 
Eligible: NR 
 
Total sample: 434 
 
Total IG: 235 (54.1%) 
 
Age: IG: M = 67 (15) 
[estimated] h, 
CG: M = 67 (16.2) 
Cite: gastrointestinal 
41.70%, lung 
11.98%, breast and 
female genitals 
15.44%, prostate and 
male genitals 9.45%, 
kidney/vesical/urethr
a 6.68%, lymphomas 
2.99%, skin 2.76%, 
Endpoints: pain 
control, physical 
functioning, 
emotional 
functioning, 
psychological 
distress 
 
Tool for 
Team:  GP, 
community nurse, 
consultant nurse or 
physician  
 
Place: PC unit/clinic 
− 
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Blinding: No 
 
Stratification: Yes  
 
1 site (community 
healthcare districts 
clustered) g 
[estimated] 
 
Gender: 53.0% M 
[estimated] (IG: 56% 
M, CG: 49% M) 
 
Inpatients and 
outpatients 
(community) 
other 8.99%   
 
Metastatic: Yes  
 
Stage: NR 
 
Previous treatment: 
NR 
 
Prognosis (T1): NR 
HRQoL: EORTC 
QLQ C-30 i 
 
 
 
Ozcelik et al  
 
2014 
 
Turkey 
 
Randomization level: 
patients 
 
Blinding: No 
 
Stratification: Yes (by 
age, gender and 
education level) 
 
1 site  
2009-
2011 
Inclusion criteria: a) 'patients 
with an acute need for PC;  b) 
> 18 years old; c) fully 
conscious cooperative and 
oriented; d) no sight or 
hearing problems; e) capable 
of verbal communication; f) 
diagnosed with advanced 
stage of cancer; g) prognosis 
6-12 months; h) KPS j ≤ 50; i) 
with 1 or more uncontrollable 
symptoms; j) receiving PC 
 
Exclusion criteria: NR 
Eligible: NR 
 
Total sample: 44 
 
Total IG: 22 (50% of 
total) 
 
Age: IG: M = 52.6 
(13.3), CG M = 53.6 
(12.3) 
 
Gender: IG: 18.2% M, 
CG: 31.8% M 
 
Inpatients 
Cite: gastrointestinal, 
genitourinary, breast, 
sarcoma, lung, and 
unknown primary 
tumour. 
 
Metastatic: Yes 
 
Stage: IV 
 
Previous treatment: 
NR 
 
Prognosis (T1): 6-12 
months 
Endpoints: 
HRQoL, 
symptoms, 
general and 
functional status, 
patient 
satisfaction, 
patient 
expenditure 
 
Tool for 
HRQoL: EORTC 
QLQ C-30 
 
 
 
Team:  Case 
Management nurse, 
Case Management 
team (RN Case 
Manager, oncologist, 
dietician, psychiatrist, 
social worker and 
physiotherapist), 
service nurses, 
consultation and with 
other specialties as 
well. 
 
Place: PC unit/clinic. 
 
Role, 
emotional, 
social and 
global scores  
 
− 
Physical and 
cognitive 
functioning. 
 
Temel et al  
 
2010 
 
USA 
 
Randomization level: 
patients 
 
2006-
2009 
Inclusion criteria: a) have 
pathologically confirmed 
metastatic non-small-cell lung 
cancer; b) diagnosed the 
previous 8 weeks; c) ECOG k 
performance status 0,1,2; d) 
sufficient English literacy. 
  
Exclusion criteria: patients 
Eligible: 283 
(calculated by the 
Suppl. Appendix I)  
 
Total sample: 151 
(74.2% of eligible) 
 
Total IG: 77 (51% of 
total) 
Cite: non-small-cell 
lung cancer (100%) 
 
Metastatic: Yes 
(brain metastases in 
31% of IG and 26% 
of CG) 
 
Stage: NR 
Endpoints: 
HRQoL (Trial 
Outcome Index 
which is the sum 
of scores of LCS 
and the physical 
and functional 
wellbeing of the 
FACT-L), mood, 
Team: Palliative care 
physician and 
advanced practice 
nurse (additional 
visits by the palliative 
care service – not 
specified what they 
entail). 
 
 
Clinically 
meaningful 
improvemen
ts 
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Blinding: No 
 
Stratification: Yes 
(matched per 
demographics and 
prognostic factors 
balanced) 
 
1 site 
already receiving PC. 
 
 
 
Age: IG: M = 64.98 
(9.73), CG: M = 64.87 
(9.41) 
 
Gender: 58.3% M (IG: 
51% M, CG: 45% M) 
 
Outpatients  
 
Previous treatment: 
platinum-based 
chemotherapy, single 
agent, oral EGFR, 
tyrosine kinase 
inhibitor, 
radiotherapy, 
chemaradiotherapy, 
initial chemotherapy 
in 21% of IG and 
27% of CG 
 
Prognosis (T1): NR 
use of health 
services and end-
of-life care 
 
Tool for 
HRQoL: FACT-
L l + the lung 
subscale (LCS) 
 
 
 
Place: Home-care 
visits 
Zimmermann et al 
 
2014 
 
Canada 
 
Randomization level: 
Oncology clinics 
(clustered) 
 
Blinding: No (but 
participants in study 
arms were not aware of 
the existence of the other 
arm – common method 
in cluster-randomized 
trials [76]AM 
 
Stratification:  Yes (by 
clinic size and cancer 
site) 
2006-
2011 
Inclusion criteria: a) > 18 
years old; b) stage IV cancer; 
c) receiving refractory to 
hormonal therapy; d) stage III 
and poor clinical diagnosis at 
the discretion of the 
oncologist; e) estimated 
prognosis 6-24 months; f) 
ECGO performance 0, 1 or 2. 
  
Exclusion criteria: a) 
insufficient English literacy; 
b) inability to pass cognitive 
screening test (Short-
Orientation-Memory-
Concentration Test Score < 20 
or > 10 errors). 
 
 
Eligible: 992 (350 
declined, 181 did not 
complete baseline 
assessment) No report 
of differences with 
those who were not 
enrolled) 
 
Total sample: 461 
(46.4% of eligible) 
 
Total IG: 228 (49.5% 
of total) 
 
Age: IG: M = 61.2 
(12), CG: M = 60.2 
(11.3) 
 
Gender: 43.4% M (IG: 
40.4% M, CG: 46.4 % 
M) 
Cite: lung (21.9%), 
gastrointestinal 
(30.2%), 
genitourinary 
(16.9%), breast 
(15.6%), 
gynecological 
(15.4%) 
 
Metastatic: NR 
 
Stage: III, IV 
 
Previous treatment: 
chemotherapy (76.3% 
of IG and 78.1% of 
CG), radiotherapy (7 
% of IG and 5.6% of 
CG) 
 
Prognosis (T1): 6-
Endpoints: 
HRQoL 
(primary); 
symptom control, 
satisfaction with 
care, problems 
with medical 
interaction 
(secondary) 
 
Tool for 
HRQoL: FACIT-
Sp m, QUAL-E n 
 
 
 
Team:  Palliative 
care physician and 
palliative care nurse 
(for outpatient clinics 
and hospital services) 
with additional 
personnel for home 
care (personal 
support, physical 
therapy and 
occupational 
therapy). 
 
Place: PC unit/clinic 
and home-care visits 
At 3 months 
 
With 
QUAL-E 
− 
With FACIT 
 
At 4 months 
 
With 
QUAL-E 
 
With FACIT 
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Notes: a. Stratification in a cluster RCT can refer to cluster characteristics like for example the clinic size in the Zimmermann study.  b. Eligible is considered the people 
assessed for eligibility excluding those who were excluded based on the exclusion/inclusion criteria. c. IG: Intervention Group. d. CG: Control Group. e. HRQoL: Health-
Related Quality of Life. f. FACIT-pal: Functional Assessment of Chronic Illness Therapy-Palliative care subscale. g. Community health care districts were stratified into 
pairs according to their number of inhabitants older than 60 and to whether they represented rural or urban areas. Eligible patients were assigned treatment according to the 
cluster-district in which they lived h. Information was estimated and was not reported. i. EORTC QLQ C-30: European Organization for Research and Treatment of Cancer 
quality of life scale. j. KPS: Karnofsky Performance Scale. k. ECOG: Eastern Cooperative Group Score. l. Functional Assessment of Cancer Therapy-Lung subscale. m. 
Functional Assessment of Chronic Illness Therapy-Spiritual wellbeing subscale. n. Quality of Life at the End of Life questionnaire.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 site (24 oncology 
clinics) 
 
Inpatients and 
outpatients (clinics and 
home care) 
24months 
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Table 2 Study characteristics of on-randomized controlled trials (RCTs) included in the review. 
Study 
information 
Study 
period 
Recruitment procedures Participants Cancer type and treatment Data collection and 
tools used 
SPC delivery Outcome 
Bischoff et al 
 
2013 
 
USA 
 
1 site 
2007-
2010 
Inclusion criteria: 
patients with any cancer 
diagnosis, stage, or 
oncologic treatments 
  
Exclusion criteria: 
patients who had 
palliative care follow-up 
within 120 days of their 
initial visit. 
 
 
Eligible a: 574 
 
Total sample: 266 (46.3% 
of eligible)   
 
Age: M = 57.2 (13.8) 
 
Gender: 46% M 
 
Inpatients 
Cite:  prostate (20%), Breast 
(19%), gastrointestinal (15%), 
gynaecologic (12%), head and 
neck (8%), non-prostate 
genitourinary (8%), lung (7%) 
 
Metastatic: Yes (59%) 
 
Stage:  NR 
 
Previous treatment:  68% on 
active oncologic treatment 
 
Prognosis (T1): NR 
Endpoints:  HRQoL, 
patients’ symptoms 
 
Tool for HRQoLb: 
Edmonton Symptom 
Assessment System 
(ESAS) 
questionnaire, one 
question from the 
QUAL-E survey 
(‘How would you 
rate your overall 
quality of life?’) 
 
 
 
Team:  Oncologists, 
palliative care 
physicians and an 
interdisciplinary team 
including a social 
worker, psychologist, 
nutritionist and a 
chaplain available for 
visits as needed by 
each patient. 
 
Place: PC unit/clinic 
First follow-
up 
 
0.26-point 
improvement 
(95 % CI 
0.09–0.42; p = 
0.002)  
 
Second 
follow-up 
 
0.33-point 
improvement 
(95 % CI 
0.10–0.56; p = 
0.02).   
 
 
Cohen et al 
 
2001 
 
Canada 
 
Multiple sites 
NR Inclusion criteria: a) 
sufficient English or 
French literacy; b) a life 
expectancy ≥ 10days; c) 
sufficient physical 
stamina to allow 
participation; d) mental 
acuity sufficient for 
informed consent and 
questionnaire completion; 
e) ≥18 years old 
Eligible: 194 
 
Total sample: 135 (69.6% 
of eligible)   
 
Age: M = 64.0 (no SD 
reported, range 46-90) 
 
Gender: 49% M 
 
Inpatients 
Cite:  Most frequent reported: 
lung (12.6%), head and neck 
(8.9%), gastrointestinal (8.1%) 
 
Metastatic: NR 
 
Stage:  NR 
 
Previous treatment:  NR 
 
Prognosis (T1): NR 
Endpoints:  HRQoL 
 
Tool for HRQoL: 
McGill Quality of 
Life Questionnaire 
 
 
 
Team: NR 
 
Place: NR 
 
MQOL-SIS, 
MQOL total, 
physical 
symptoms, 
psychological, 
existential, 
and physical 
wellbeing.   
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Exclusion criteria: NR 
 
 
Echteld et al 
 
2007 
 
The 
Netherlands 
 
1 site 
2004-
2005 
Inclusion criteria: a) 
sufficient Dutch literacy; 
b) no limitations of 
consciousness (i.e. 
somnolence); c) no 
cognitive deficits (i.e. 
resulting from cerebral 
damage); d) likely 
admission duration of one 
week or longer 
(physician’s estimate). 
  
Exclusion criteria: NR 
 
 
Eligible: 60 
 
Total sample: 29 (pre-
intervention), 16 (post-
intervention).   
 
Age: Pre-intervention: M = 
55.3, Post-intervention: M 
= 60.6. 
 
Gender: Pre-intervention: 
31% M, Post-intervention: 
31.3% M 
 
Inpatients 
Cite:  Lung (20.7%), breast 
(13.8%), colorectal (13.8%), 
melanoma (10.3%), sarcoma 
(6.9%), urogenital for women 
(6.9%), urogenital for men 
(3.4%), unknown primary site 
(24.1%) 
 
Metastatic: NR 
 
Stage:  NR 
 
Previous treatment:  NR 
 
Prognosis (T1): NR 
Endpoints:  HRQoL, 
pain, fatigue, 
reconceptualization 
of cues. 
 
Tool for HRQoL: 
Schedule for the 
Evaluation of 
Individual Quality of 
Life 
 
 
 
Team:  Two nurse 
coordinators 
 
Place: PC unit/clinic 
 
ES = 0.60  
 
  
Melin-
Johansson et 
al 
 
2010 
 
Sweden 
 
1 site 
2003-
2005 
Inclusion criteria: a) 
patients who were aware 
of diagnosis and 
prognosis; b) ≥ 18 years 
old; c) sufficient Swedish 
literacy; d) ability to 
complete questionnaires 
independently; e) 
intended place of care: 
private homes 
  
Exclusion criteria: a) 
prognosis of less than 
1month, as estimated by 
the team; b) other 
diagnoses than cancer; c) 
Eligible: 163 
 
Total sample: 63 (38.7% 
of eligible)  
 
Age: Mdn=72 (range 24-
90) 
 
Gender: 57.1% M 
 
Outpatients 
Cite: prostate (28.7%), lung 
(11.1%), breast (6.3%), stomach 
(9.5%), colon (19%), 
gynaecological (6.3%), liver 
(3.2%), other (15.9%) 
[percentages estimated not 
reported] 
 
Metastatic: Yes 
 
Stage: NR (incurable cancer) 
 
Previous treatment: NR 
 
Prognosis (T1):  NR  
Endpoints:   HRQoL 
 
Tool for HRQoL: 
Assessment of 
Quality of Life at the 
End of Life (AQEL)  
(α = 0.74) 
  
 
 
Team:  Seven full-time 
registered nurses and 
two part-time 
physicians with 
specific training in 
palliative care and long 
clinical experience of 
caring for this 
population 
 
Place: Home-care 
visits 
 
Global QoL  
 
− 
Social and 
existential 
domains.  
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failing to give informed 
consent  
 
 
Stromgren et 
al 
 
2005 
 
Denmark 
 
1 site 
1998-
2000 
Inclusion criteria: a) 
referred for symptom 
control, b) advanced stage 
cancer with no curative 
treatment options, c) with 
‘pronounced palliative 
needs., d) Danish 
speaking, e)  ≥ 18 years, 
f) able to give consent. 
 
Exclusion criteria: NR 
Eligible: 267  
 
Total sample: 175 (65.5% 
of eligible)   
 
Age: Mdn = 63 (range 37-
91) 
 
Gender: 44% M 
 
Inpatients and outpatients 
Cite: head and neck (4.6%), 
gastrointestinal tract (20.6%), 
respiratory system (26/3%), 
breast (17.1%), genitourinary 
(16.6%), gynecologic (6.9%), 
sarcoma (1.1%), melanoma/skin 
(2.9%), hematologic (1.1%), 
unknown (2.9%).  
 
Metastatic: Yes 
 
Stage: NR (incurable cancer) 
 
Previous treatment: NR 
 
Prognosis (T1):  Mdn = 35 days 
(range 3-1217 days) 
Endpoints:   
HRQoL, anxiety, 
depression, 
orientation, memory, 
attention. Fatigue. 
 
Tool for HRQoL: 
EORTC QLQ C-30, 
ESAS 
 
Team:  Physicians 
(oncology, 
anesthesiology, 
internal medicine), 
nurses, social workers, 
chaplains, 
psychologists, physical 
therapists and 
dieticians 
 
Place: PC unit/clinic 
 
Global QoL, 
nausea/vomiti
ng, pain, lack 
of appetite, 
sleeplessness, 
constipation.   
Yamagishi et 
al 
 
2014 
 
Japan 
 
Multiple sites 
(4 regions) 
2008-
2011 
Inclusion criteria: a) 
adults with metastatic or 
recurrent cancer; b) 
outpatient visits to the 
oncology or each 
specialty division; c) the 
patient had been informed 
of the malignancy. 
  
Exclusion criteria: a) 
inability to complete the 
questionnaire (dementia, 
cognitive failure, 
psychiatric illness, 
Eligible: 1488 (pre-
intervention), 1501 (post-
intervention) 
 
Total sample: 859 (pre-
intervention, 57.7 % of 
eligible), 857 (post 
intervention, 57.1% of 
eligible)  
 
Age: Pre-intervention: M = 
67.0 (11.0), Post-
intervention: M = 68.0 
(11.0) 
Cite:  Lung (26%), breast 
(16%), colorectal (14.5%), 
prostate, kidney, and bladder 
(14.5%), stomach and esophagus 
(10%), liver, bile duct, and 
pancreas (10%), uterus and 
ovary (6%) 
 
Metastatic: Yes 
 
Stage:  NR (Advanced) 
 
Previous treatment:  
Chemotherapy and radiotherapy 
Endpoints:  Home 
death, use of a 
palliative care 
service, and patient-
reported and 
bereaved family-
reported quality of 
palliative care. 
 
Tool for HRQoL:  
Good Death 
Inventory, Care 
Evaluation Scale 
 
Team:  NR 
But methodological 
paper indicates that a 
clinician, a nurse, and a 
medical social worker 
were delivering the 
intervention. 
 
Place: Community-
based 
 − 
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Notes: a. Eligible are considered the people assessed for eligibility excluding those who were excluded based on the exclusion/inclusion criteria. b. HRQoL: Health-Related 
Quality of Life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
language difficulty, or 
visual loss); b) severe 
emotional distress as 
determined by the 
principal treating 
physicians; c) poor 
physical condition  
 
 
 
Gender: Pre-intervention: 
55% M, post-intervention: 
60% M 
 
Outpatients 
 
Prognosis (T1): NR 
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Table 3 Description of intervention and control procedures of included studies in the review  
 
Study Intervention 
name 
Intervention 
background (i.e. 
theoretical) 
Training towards 
people delivering the 
intervention 
Duration of 
intervention 
Intervention group procedures Control group 
procedures 
Bakitas et al 
 
2009 
 
USA 
ENABLE 
(Educate, 
Nurture, 
Advise, Before 
Life Ends) 
Palliative care is based on 
the chronic care model, 
using a case 
management, educational 
approach to encourage 
patient activation, self-
management, and 
empowerment. Authors 
refined and converted the 
in-person and group 
strategies used in their 
previous studies. The 
intervention emphasized 
the importance of patients 
taking an active role in 
openly communicating 
with family and the 
oncology team regarding 
their values, priorities, 
and treatment 
preferences. 
NR No. of sessions: 4 
weekly educational 
sessions. Ongoing 
support and coaching 
of patients by 
telephone until death. 
 
Follow-ups: every 3 
months until death 
 
Follow-up time: 
Mean follow-up 
months = 14.6 (12.8). 
 
Total duration: 4 
years 
Advanced practice nurse–administered, 
telephone-based, intensive curriculum, and 
ongoing assessment and coaching in problem 
solving, advance care planning, family and 
health care team communication strategies, 
symptom management and crisis prevention, 
and timely referral to palliative care and 
hospice resources. Intervention participants and 
their caregiver were invited to attend monthly 
group Shared Medical Appointments (SMAs) 
led by a certified palliative care physician and 
nurse practitioner. These appointments allowed 
participants and caregivers to ask questions 
about medical problems or related issues (i.e., 
symptom management, insurance, social 
services) and to have more in-depth discussions 
than is practical during typical clinic visits. 
Received usual care: 
allowed to use all 
oncology and 
supportive services, 
without restrictions 
including referral to 
the institutions’ 
interdisciplinary 
palliative care 
service. 
Bischoff et al 
 
2013 
 
USA 
None NR NR No. of sessions: 
Visits scheduled as 
frequently as needed 
by the patients 
 
Follow-ups: 2 
 
Follow-up time: 41 
and 81 days after 
Patients were typically referred to the 
palliative care clinic by an oncologist and 
were followed by their oncologists after 
referral. The palliative care team coordinated 
their care with the oncologist, rendering a 
system of palliative and oncologic co-
management. Initial visits typically involved 
medication management for pain, mood, and 
fatigue; Detailed prognosis discussions and 
N/A 
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initial assessment 
 
Total duration: 120 
days 
advance care planning typically occurred 
during subsequent visits. Opioids, non-opioid 
analgesics, antidepressants, anxiolytics, 
psychostimulants, laxatives, and antiemetic 
were the most common medications 
prescribed. Symptom management 
medications were prescribed directly by the 
palliative care physician. The majority of 
patient care was done during clinic visits; 
however, patients were able to communicate.  
Cohen et al 
 
2001 
 
Canada 
None NR NR No. of sessions: NR 
 
Follow-ups: NR 
 
Follow-up time: NR 
 
Total duration: NR 
NR N/A 
Echteld et al 
 
2007 
 
The 
Netherlands 
None NR NR No. of sessions: 
Daily until hospital 
discharge (1-2 weeks) 
 
Follow-ups: Daily 
until hospital 
discharge (1-2 weeks) 
 
Follow-up time: 
Daily 
 
Total duration: 1-2 
weeks 
The purpose of the Unit was to provide 
symptom control (primarily pain) to advanced 
cancer patients, and thus facilitate discharge 
after adequate levels of symptom control have 
been reached. 
N/A 
Jordhøy et al 
 
2001 
Palliative 
Medicine Unit 
(PMU) 
NR An educational 
program for the 
community 
No. of sessions: NR 
 
Follow-ups: 7 
Individual treatment plans were set up in a 
joint meeting between the patient, the informal 
caregiver, the general practitioner (GP), the 
NR 
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Norway 
program professionals included 
bedside training and 6 
to 12 hours of lectures 
every 6 months. 
 
Follow-up time: first 
6 months after trial 
entry (monthly) and 2 
years 
 
Total duration: NR 
community nurse, and a consultant nurse or 
physician from the PMU. Follow-up 
consultations by the GP and the community 
nurse were arranged according to the patients’ 
needs and predefined minimum standards. 
Hospital service was offered on request and 
always at the PMU, that is, unless otherwise 
required for medical reasons (i.e., surgery). 
The PMU consultant team participated in the 
inpatient care, handled the PMU outpatient 
clinic, coordinated the follow-up, and was 
available to the community staff for 
supervision and advice and to join visits in the 
patient’s home. 
Melin-
Johansson et 
al 
 
2010 
 
Sweden 
Palliative 
Homecare 
Teams (PHTs) 
NR NR No. of sessions: NR 
 
Follow-ups: NR 
 
Follow-up time: NR 
 
Total duration: 2 
weeks 
The aim of the intention is to minimize patient 
and family suffering by delivering effective, 
individualized palliative care, to support the 
patient’s wish to stay at home as long as 
possible and to maintain an acceptable level of 
HRQoL (5-days-a-week consultations). It is 
complementary to hospitalized care and 
community healthcare services. During 
evenings, nights and weekends the district 
nurses on call in the county were in charge of 
the care. Interventions at home visits could 
include intravenous fluid therapy, blood 
transfusions, chemotherapy and other forms of 
technical support. The team also used specific 
methods for symptom control (e.g. for pain) 
and provided psychological, social and 
emotional support. 
N/A 
Ozcelik et al 
 
2014 
 
None Case Management 
palliative care 
A mode of delivering 
the intervention is 
provided but no 
specific indication of 
No. of sessions: NR 
 
Follow-ups: NR 
 
Received symptom diagnosis at T1 and 
organized effective symptom management, 
psychosocial stress management, social 
support, care and training support and family 
Assessment by 
oncologist who 
organized usual 
treatment care. Usual 
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Turkey how the team was 
trained 
Follow-up time: NR 
 
Total duration: NR  
counseling services. Monitored by and 
discharged by the Care Team. The PC 
Protocol in Advance Care Planning was used.   
nursing care 
provided. Clinic 
routines applied. 
Strömgren et 
al 
 
2005 
 
Denmark 
None Referred to as SPC Unit 
for symptom control and 
end-of-life care planning.  
NR  No. of sessions: 3 
 
Follow-ups: 3 
 
Follow-up time: 1 
week 
 
Total duration: 3 
weeks 
NR NA 
Temel et al 
 
2010 
 
USA 
None Specific attention to 
assessing physical and 
psychosocial symptoms, 
establishing care goals, 
assisting with treatment 
decision-making and 
coordinating care based 
on patients’ needs 
The palliative care 
clinicians documented 
provision of care 
according to the 
National Consensus 
Project for Quality PC 
guidelines (Clinical 
Practice guidelines for 
quality palliative care 
2009 ref 14). No other 
training reported.  
No. of sessions: 
Average 4 (range 0-
8) 
 
Follow-ups: 1 
 
Follow-up time: 12 
weeks (or at 
outpatient clinic visits 
within 3 weeks 
before or after the 12 
week time point). 
 
Total duration: 12 
weeks 
Early palliative care integrated with standard 
oncologic care. Information provided in 
study’s Suppl. Appendix I on components: 
illness understanding/education, symptom 
management, decision-making, coping with 
life threatening illness, referrals/prescription. 
No meeting with PC 
services unless 
requested. Those who 
did were not assigned 
to the PC group but 
kept to initial group. 
Received standard 
oncologic care. 
Yamagishi et 
al 
 
2014 
 
Japan 
Japan Outreach 
Palliative care 
Trial of the 
Integrated 
Model (the 
OPTIM study) 
NR 
But methodological paper 
[77] provides information 
that the intervention was 
based on a scoping 
literature review and 
some preliminary surveys 
and discussions (between 
NR 
But methodological 
paper indicates that 
local leaders of the 
intervention received a 
2-day workshop before 
the intervention, 25 
meetings took place 
No. of sessions: NR 
 
Follow-ups: NR 
 
Follow-up time: NR 
 
Total duration: NR 
Comprehensive program covering four areas: 
1) to improve the knowledge and skills of 
palliative care; 2) to increase the availability 
of SPC services for community patients; 3) to 
coordinate community palliative care 
resources; and 4) to provide appropriate 
information about palliative care to the 
general public, patients, and families. 
N/A 
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researchers and 
healthcare professionals 
in the study regions).  
during the intervention 
and a community nurse 
followed up by phone 
and email. Local 
leaders were provided 
with palliative care 
manuals. 
Zimmermann 
et al 
 
2014 
 
Canada 
None Approach to care 
declared as 
multidisciplinary 
addressing physical, 
psychological, social and 
spiritual needs.   
In Hospital Services 
formal 10-day training 
at opening for 
palliative care unit and 
continuous education 
offered to palliative 
care nurses. Also, a 
detailed report on 
intervention procedures 
is outlined.   
No. of sessions: 4 
monthly sessions 
(primary endpoint = 
month 3, secondary 
endpoint = month 4). 
 
Follow-ups: 4 
 
Follow-up time: 1 
month 
 
Total duration: 4 
months 
Outpatient clinics: structured symptom 
assessment, psychological assessment 
(including discussions around care goals, 
patient and family support needs, distress and 
coping), advanced care planning. Patients 
were routinely assessed by telephone follow-
up by a nurse after each visit and 24-h on-call 
service provided by palliative care physicians. 
Hospital service: symptom assessment and 
follow-up by palliative care team when 
admitted to non-palliative care unit service, 
Home care: explained at first visit, reassessed 
at each visit. A home palliative care physician 
offered when ECOG performance status ≥3 or 
at request of patient. 
No palliative care 
received but a referral 
initiated if requested. 
In which case they 
were offered same 
care with IG but not 
the same standardized 
monthly follow-up. 
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Table 4 Quality assessment of included studies in the review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: Scoring: 2 = well-covered criterion, 1 = moderately or poorly addressed, 0 = not addressed. NA = Not Applicable 
Criteria used: A - Objectives and hypotheses, B - Baseline assessment, C – Selection bias, D - Intervention explained, E – Primary outcome measures, F – Confounding 
variables, G – Power, H – Adherence to protocol, I – Precision, J – Attrition, K – Differential attrition, L – Intention-to-treat analysis, M – Generalizability, N – 
Randomization: Sequence generation, O – Randomization: Allocation concealment, P – Blinding procedures.          
NA = Non Applicable (these criteria are relevant only for Randomized-Controlled Trials).  
 
 
Study A B C D E F G H I J K L M N O P Total Score 
Bakitas et al 2 2 2 2 2 1 1 2 1 1 1 2 2 2 2 0 25/32 (78.1%) 
Bischoff et al 2 2 NA 1 1 1 0 0 1 1 0 NA
 1 NA NA NA 10/22 (45.5%) 
Cohen et al 1 2 NA 0 2 1 0 0 0 1 0 NA 1 NA NA NA 8/22 (36.4%) 
Echtlend et al 1 2 NA 0 1 1 0 1 0 1 1 NA 1 NA NA NA 9/22(40.9%) 
Jordhoy et al 2 2 1 1 2 1 1 1 0 2 1 0 1 2 0 0 17/32 (53.1%) 
Melin-Johansson et al 2 2 NA 1 2 1 0 1 1 1 2 NA 1 NA NA NA 14/22 (63.6%) 
Ozcelik et al 2 2 1 1 2 0 1 2 0 2 1 0 1 2 0 0 17/32 (53.1%) 
Stromgren  1 2 NA 1 2 1 1 1 1 2 2 NA 1 NA NA NA 15/22 (68.2%) 
Temel et al 2 2 2 1 2 1 2 2 1 2 2 0 1 0 0 0 20/32 (62.5%) 
Yamagishi et al 2 2 NA 1 1 1 0 1 0 1 0 NA 1 NA NA NA 10/22 (45.5%) 
Zimmerman et al 2 2 1 2 2 1 2 2 1 2 1 0 2 2 1 2 25/32 (78.1%) 
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Fig 1 Flow Diagram of study identification and selection 
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Fig 2 The attrition rates reported from baseline to end of study 
 
 
Notes: Attrition for Yamagishi et al (2014) not reported since different participants responded to assessments pre- and post- the intervention.  For Strömgren et al (2005) the 
3rd week is used as T2 because the paper reports HRQoL changes in the 3rd week post- intervention.  
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Fig 3 Meta-analysis results of included studies 
 
Notes: The figure presents the results of the meta-analysis favoring either the intervention or control arms of all studies, the RCTs only, or the non-RCTs only. Moreover, the 
funnel plot presents the publication bias of the included studies.   
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PRISMA Flow Diagram 
 
Articles identified through database 
searching (n= 8649) 
(MEDLINE n= 645, PsychINFO n= 
1250, EMBASE n= 2541, CENTRAL 
n= 1594, PubMed n= 2615) 
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Additional articles identified 
through additional sources (n = 4) 
Articles after duplicates removed 
(n= 7726) 
Articles screened based on title 
relevance (n= 1729) 
Articles excluded (n= 921) with reasons: 
other treatment (n= 228), other language (n= 
117), other design (n= 4), other population 
(n= 50), no intervention (n= 522) 
Articles assessed for eligibility 
based on abstract (n = 808) 
Articles excluded, with reasons (n= 789): 
other design (n= 200), no intervention (n= 
100), other treatment (n= 226), not 
published/completed (n= 69), other outcome 
(n= 43), duplicates (n= 38), other language 
(n= 10), other population (n= 25), 
feasibility/pilot studies (n= 10), not found 
(n= 31), no trial/correlational studies (n=37) 
Articles included in qualitative 
synthesis (n = 12) 
Articles included in quantitative synthesis 
(meta-analysis) (n = 11) 
Articles screened based on inclusion of 2 
keywords in title (n= 7726) 
Articles excluded 
(n= 5997) 
Full-text articles assessed for 
eligibility (n =19) 
Articles excluded: not providing separate 
results for cancer patients (n = 1), based on 
clinical evaluation as intervention not 
delivered by palliative care specialists (n = 6) 
 
1 article excluded because of not providing 
enough and clear statistics to calculate the 
effect size 
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